Loading clinical trials...
Loading clinical trials...
Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC): a Phase I Trial to Identify a Dose of Dacomitinib in Combination With Pemetrexed That is Safe and Tolerated as Determined by the Incidence of Dose Limiting Toxicities (DLTs)
Conditions
Interventions
Dacomitinib, Pemetrexed
Locations
2
Austria
Medizinische Universität Graz Klinische Abteilung für Onkologie
Graz, Austria
Universitätsklinik für Innere Medizin I
Innsbruck, Austria
Start Date
July 30, 2013
Primary Completion Date
September 15, 2016
Completion Date
September 15, 2016
Last Updated
December 30, 2019
NCT06066138
NCT07485114
NCT05098132
NCT06284317
NCT06731413
NCT06687369
Lead Sponsor
Central European Cooperative Oncology Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions